MetLife, Inc. logo MET - MetLife, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 25
HOLD 8
SELL 0
STRONG
SELL
0
| PRICE TARGET: $101.00 DETAILS
HIGH: $111.00
LOW: $90.00
MEDIAN: $103.00
CONSENSUS: $101.00
UPSIDE: 3.97%
AlphaVal

AlphaVal

Deterministic, archetype-aware fair value

Banks, Insurers & Asset Managers 85% confidence

Primary model: P/Tangible Book × ROE Quality

Valuation Signal Overvalued Mild
Trading 9.0% above fair value
Current Price $97.14
Bear Case $62.37 35.8% downside ($62.37 - $97.14) / $97.14 = -35.8% ROTCE 8.9% → 1.10x TBV
Fair Value $89.10 8.3% downside ($89.10 - $97.14) / $97.14 = -8.3% ROTCE 11.9% → 1.77x TBV
Bull Case $115.83 19.2% upside ($115.83 - $97.14) / $97.14 = 19.2% ROTCE 13.7% → 2.16x TBV

Adjust Assumptions

11.9%
8.5%

Key Value Driver

ROTCE (11.9%) vs. cost of equity (8.5%)

Implied Market Multiple 2.2x

Plain-Language Summary

With ROTCE of 11.9% vs. 8.5% cost of equity, fair P/TBV is 1.77x on $44.13 tangible book, implying $89.10 per share. DDM cross-check: $47.57.

Analyst Consensus (External Reference)

Never blended into the bear/base/bull estimates above -- shown only as an outside comparison.

Average Target (33 analysts) $101.00
Analyst Range $90.00 – $111.00
Divergence from AlphaVal 12%

Warnings

Traditional cash flow models don't work well for banks — lending activity distorts how much cash the business actually generates.
Common valuation shortcuts don't apply here — for banks, interest payments are a core business cost, not overhead.
Dividend-based valuation: $47.57 (47% below our primary estimate). Large gaps suggest the dividend may not fully reflect the company's value.

Key Risks

  • Book value quality matters as much as level — check loan loss reserves
  • Interest rate sensitivity creates non-linear earnings surprises
  • Insurance reserving is actuarial, not financial — errors emerge slowly